Israel Stocks: Ampal-American, Bioline, Ceragon, Elbit Systems

Israel’s TA-25 Index advanced for a second day, increasing 0.3 percent to 1,291.85 at 12:45 p.m. in Tel Aviv.

The following stocks rose or fell today. Symbols are in parentheses.

Ampal-American Israel (AMPL) Corp climbed the most since March 16, jumping 9.1 percent to 4.388 shekels. The owner of a 12.5 percent stake in East Mediterranean Gas Co. said gas deliveries to Israel may resume at the end of the month once new security measures have been implemented.

Separately, the company reported first-quarter net income of $17.2 million after a year-earlier loss.

Bioline RX (BLRX IT) gained for the first time in seven days, rising 2.6 percent to 1.93 shekels. The biopharmaceutical company said it’s developing BL-7030 for targeted cancer therapy.

Ceragon Networks Ltd. (CRNT) fell to the lowest since March 24, dropping 4.6 percent to 38.39 shekels. The wireless networking-systems developer reported a first-quarter loss of $21.4 million after a profit of $3 million a year earlier.

Clal Biotechnology Industries Ltd. (CBI) rose the most in almost a week, advancing 2.1 percent to 20.54 shekels. CureTech, a unit of the investor in biological companies and Teva Pharmaceutical Industries Ltd. (TEVA) said CT-011 met its primary endpoint in a Phase II trial in patients with Diffuse Large B Cell Lymphoma. Teva slipped 0.7 percent to 174.70 shekels.

Elbit Systems Ltd. (ESLT) climbed the most since April 11, adding 2.2 percent to 183.10 shekels. Israel’s biggest non- government defense contractor won an order worth $32.7 million to supply an unidentified Asian army with advanced training systems for its armor and infantry forces.

To contact the reporter on this story: Ronit Goodman in Tel Aviv at

To contact the editor responsible for this story: Claudia Maedler at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.